Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Acrivon announced that dose escalation data for ACR-2316, its first-in-class oral WEE1/PKMYT1 inhibitor, will be presented in a late-breaking oral plenary session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026. The Phase 1/2 data show durable clinical activity in heavily pretreated, AP3-predicted tumors, including a confirmed complete response in a squamous NSCLC patient after four prior lines of therapy and responses in endometrial and lung cancers, with several patients on treatment over one year.
Key figures
- Drug Name
- ACR-2316
- Phase Of Trial
- Phase 1/2
- Symposium
- 38th EORTC-NCI-AACR Symposium
- Abstract number
- 11LBA
- Presentation date
- November 20, 2026
- Median prior lines therapy
- 3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.